#1 Clinical Trials Search in Europe

Teprenone

Teprenone, also known as geranylgeranylacetone (GGA), is a drug that has been the subject of several clinical trials investigating its potential benefits in various medical conditions. These trials have primarily focused on its effects on gastric health, including the prevention of ulcers and treatment of gastritis, as well as its potential role in heart failure management. The studies aim to evaluate Teprenone’s efficacy, safety, and mechanisms of action in comparison to other treatments or placebos.

Table of Contents

What is Teprenone?

Teprenone, also known by its alternative name Geranylgeranylacetone (GGA), is a medication primarily used to protect the gastrointestinal tract[1]. It belongs to a class of drugs called mucosal protective agents, which means it helps to safeguard the lining of the stomach and intestines[2].

Medical Conditions Treated with Teprenone

Teprenone is used to treat and prevent several gastrointestinal conditions, including:

  • Gastric or duodenal ulcers: These are sores that develop on the lining of the stomach or the first part of the small intestine (duodenum)[1].
  • Chronic erosive gastritis: This is a condition where the stomach lining is gradually worn away, leading to inflammation[2].
  • NSAIDs-related gastrointestinal side effects: Teprenone can help prevent and treat stomach problems caused by non-steroidal anti-inflammatory drugs (NSAIDs), which are commonly used for pain relief[3].

How Teprenone Works

Teprenone works by protecting and strengthening the mucosal lining of the stomach and intestines. It does this in several ways:

  • Increasing the production of protective substances in the stomach, such as prostaglandin E2 (PGE2) and heat shock protein 70 (HSP70)[2].
  • Enhancing blood flow to the stomach lining, which helps in healing and protection[2].
  • Reducing inflammation in the gastrointestinal tract[3].

Dosage and Administration

The typical dosage of Teprenone varies depending on the condition being treated:

  • For prevention of ulcers: 50 mg taken three times daily after meals[1].
  • For treatment of chronic erosive gastritis: 50 mg taken three times daily for 8 weeks[2].
  • For prevention of NSAIDs-related side effects: 50 mg taken three times daily[3].

It’s important to note that these dosages are based on clinical trials and may vary depending on individual patient needs. Always follow your doctor’s instructions regarding dosage and duration of treatment.

Clinical Studies and Effectiveness

Several clinical studies have been conducted to evaluate the effectiveness of Teprenone:

  • A study called the “Planetarium Study” compared Teprenone to another drug (E3810) in preventing recurrent ulcers in patients taking low-dose aspirin[1].
  • Another study evaluated Teprenone’s efficacy in treating chronic non-atrophic erosive gastritis in Chinese patients, comparing it to a drug called sucralfate[2].
  • A third study looked at Teprenone’s protective effects against NSAIDs-related gastrointestinal side effects, particularly in patients with rheumatic diseases[3].

These studies have generally shown Teprenone to be effective in protecting the gastrointestinal tract and treating various stomach conditions.

Potential Side Effects

While Teprenone is generally well-tolerated, like all medications, it may cause side effects in some people. Common side effects may include:

  • Mild gastrointestinal discomfort
  • Nausea
  • Constipation

It’s important to note that severe side effects are rare. However, if you experience any unusual or severe symptoms while taking Teprenone, you should contact your healthcare provider immediately.

Ongoing Research

Interestingly, recent research is exploring the potential use of Teprenone (also known as Geranylgeranylacetone or GGA) in treating heart conditions. A study is currently evaluating its effectiveness in patients with heart failure with preserved ejection fraction[4]. This condition is a type of heart failure where the heart muscle becomes stiff but still pumps normally. The study aims to determine if GGA can improve heart function and blood flow in these patients.

This ongoing research suggests that Teprenone may have broader applications beyond gastrointestinal protection, potentially offering benefits for heart health as well. However, it’s important to note that this is still in the research phase and not an approved use of the medication.

Aspect Details
Main Conditions Studied Gastric/duodenal ulcers, chronic erosive gastritis, NSAID-related gastrointestinal side effects, heart failure with preserved ejection fraction
Dosage Forms Oral capsules or tablets
Common Dosage 50 mg three times daily or 150 mg total daily dose
Comparator Treatments Rabeprazole, sucralfate, placebo
Primary Outcome Measures Ulcer recurrence rates, gastric mucosal condition, clinical symptom improvement, cardiac function parameters
Secondary Outcome Measures Bleeding ulcer incidence, histological improvements, changes in biomarkers, quality of life assessments
Safety Monitoring Adverse events, serious adverse events, treatment-emergent adverse events
Study Designs Randomized, double-blind, placebo-controlled, parallel-group, crossover

FAQ

  • What is Teprenone used for in clinical trials? Teprenone is being studied for various uses, including the prevention of gastric or duodenal ulcers in patients taking low-dose aspirin, treatment of chronic non-atrophic erosive gastritis, prevention of NSAIDs-related gastrointestinal side effects, and potential benefits in heart failure with preserved ejection fraction.
  • How is Teprenone administered in these trials? In the trials, Teprenone is typically administered orally. The dosage varies, but common regimens include 50 mg three times daily after meals, or a total daily dose of 150 mg.
  • What are some of the primary outcomes measured in Teprenone trials? Primary outcomes in Teprenone trials include the recurrence rates of gastric or duodenal ulcers, changes in gastric mucosal conditions (assessed by endoscopy and histology), improvements in clinical symptoms, and in cardiac trials, changes in heart function parameters such as filling pressures and endothelial function.
  • How does Teprenone compare to other treatments in these trials? Teprenone is often compared to other treatments or placebos. For example, in gastric ulcer prevention, it's compared to rabeprazole. In gastritis treatment, it's compared to sucralfate. The trials aim to determine if Teprenone is superior, equivalent, or inferior to these comparators.
  • Are there any side effects or safety concerns associated with Teprenone in these trials? While specific side effects are not detailed in the provided trial information, safety is a key consideration in all clinical trials. Some studies include monitoring for adverse events, serious adverse events, and treatment-emergent adverse events to assess the safety profile of Teprenone.

Ongoing Clinical Trials on Teprenone

  • Study on Teprenone for Preventing Atrial Fibrillation After Heart Surgery in Patients

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Teprenone: Also known as geranylgeranylacetone (GGA), it is a medication being studied for its potential benefits in gastric health and heart conditions.
  • NSAIDs: Non-Steroidal Anti-Inflammatory Drugs, a class of medications used to reduce pain, fever, and inflammation.
  • Gastric or Duodenal Ulcers: Open sores that develop on the lining of the stomach (gastric) or the upper part of the small intestine (duodenal).
  • Chronic Non-Atrophic Erosive Gastritis: A condition characterized by inflammation and erosion of the stomach lining, without significant loss of stomach glands.
  • Heart Failure with Preserved Ejection Fraction: A type of heart failure where the heart's ability to pump blood is normal, but it has trouble relaxing and filling with blood.
  • Endoscopy: A procedure that uses a long, flexible tube with a camera to examine the inside of the body, particularly the digestive tract.
  • Echocardiography: An imaging test that uses sound waves to create pictures of the heart's chambers, valves, walls, and blood vessels.
  • Helicobacter pylori (HP): A type of bacteria that can infect the stomach and is a common cause of ulcers.
  • Endothelial Function: The ability of the inner lining of blood vessels (endothelium) to dilate and constrict properly in response to various stimuli.
  • Diastolic Function: The heart's ability to relax and fill with blood between beats.

References

  1. https://clinicaltrials.gov/study/NCT01397448
  2. https://clinicaltrials.gov/study/NCT01284647
  3. https://clinicaltrials.gov/study/NCT01547559
  4. https://clinicaltrials.gov/study/NCT05672134